IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

BACKGROUND: Immunotherapy targeting GD2 is very effective against high-risk neuroblastoma, though administration of anti-GD2 antibodies induces severe and dose-limiting neuropathic pain by binding GD2-expressing sensory neurons. Previously, the IgG1 ch14.18 (dinutuximab) antibody was reformatted int...

Descripción completa

Detalles Bibliográficos
Autores principales: Stip, Marjolein C, Evers, Mitchell, Nederend, Maaike, Chan, Chilam, Reiding, Karli R, Damen, Mirjam J, Heck, Albert J R, Koustoulidou, Sofia, Ramakers, Ruud, Krijger, Gerard C, de Roos, Remmert, Souteyrand, Edouard, Cornel, Annelisa M, Dierselhuis, Miranda P, Jansen, Marco, de Boer, Mark, Valerius, Thomas, van Tetering, Geert, Leusen, Jeanette H W, Meyer-Wentrup, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364159/
https://www.ncbi.nlm.nih.gov/pubmed/37479484
http://dx.doi.org/10.1136/jitc-2023-006948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364159/
https://www.ncbi.nlm.nih.gov/pubmed/37479484
http://dx.doi.org/10.1136/jitc-2023-006948

Ejemplares similares